AC8 — Auscann group Share Price
Last trade - 00:00- AU$36.57m
- AU$22.81m
- AU$0.23m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.82 | ||
| Price to Tang. Book | 1.34 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 157.15 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -19.45% | ||
| Return on Equity | -21.86% | ||
| Operating Margin | -3717.63% | ||
Financial Summary
| Year End 30th Jun | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.1 | 0.24 | 0.86 | 0.39 | 0.23 | n/a | n/a | 111.64% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health Trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AusCann Group Holdings Limited is an Australia-based company, which is engaged in the development and commercialization of cannabinoid-derived therapeutic products for humans and animals. The Company focuses on providing healthcare professionals and veterinarians with pharmaceutical and nutraceutical products to support the treatment of their patients. Its controlled-dose technology platform, Neuvis, is for delivering cannabinoids to human patients through CannPal Animal Therapeutics Pty Ltd. DermaCann is its lead cannabidiol (CBD) derived nutraceutical in development for healthy skin and immune function in dogs with dermatological conditions. CPAT-01 is a liquid, oral veterinary medicine containing tetrahydrocannabinol (THC) and CBD whole plant extracts in a combined ratio to cure pain and inflammation in dogs. CPAT-01 is in Phase II clinical trials. AusCann Operations Pty Ltd and CannPal Animal Therapeutics Limited are its subsidiaries.
Directors
- Tod McGrouther CHM (57)
- Layton Mills CEO
- Charles Altshuler CFO
- Maria Alexakis OTH
- Susan Hunter SEC
- Krista Bates NED
- Robert Clifford NED
- Christopher Mews NED
- Last Annual
- June 30th, 2021
- Last Interim
- June 30th, 2021
- Incorporated
- February 26th, 1986
- Public Since
- May 3rd, 1989
- No. of Shareholders
- 16,272
- No. of Employees
- 27
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 440,547,110
- Address
- Wangara, PERTH, 6947
- Web
- https://auscann.com.au/
- Phone
- +61 863050705
- Auditors
- PKF Perth
Latest News for AC8
Upcoming Events for AC8
Half Year 2022 Auscann Group Holdings Ltd Earnings Release
Similar to AC8
Acrux
Australian Stock Exchange - SEATS
AFT Pharmaceuticals
Australian Stock Exchange - SEATS
Althea group
Australian Stock Exchange - SEATS
Benitec Biopharma
Australian Stock Exchange - SEATS
Biome Australia
Australian Stock Exchange - SEATS
FAQ
As of Today at 18:13 UTC, shares in Auscann group are trading at AU$0.08. This share price information is delayed by 15 minutes.
Shares in Auscann group last closed at AU$0.08 and the price had moved by -56.32% over the past 365 days. In terms of relative price strength the Auscann group share price has underperformed the ASX All Ordinaries Index by -60.85% over the past year.
There is no consensus recommendation for this security.
Auscann group does not currently pay a dividend.
Auscann group does not currently pay a dividend.
Auscann group does not currently pay a dividend.
To buy shares in Auscann group you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of AU$0.08, shares in Auscann group had a market capitalisation of AU$36.57m.
Here are the trading details for Auscann group:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: AC8
Based on an overall assessment of its quality, value and momentum Auscann group is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Auscann group. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -22.57%.
As of the last closing price of AU$0.08, shares in Auscann group were trading -18.67% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Auscann group PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.08.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Auscann group's management team is headed by:
- Tod McGrouther - CHM
- Layton Mills - CEO
- Charles Altshuler - CFO
- Maria Alexakis - OTH
- Susan Hunter - SEC
- Krista Bates - NED
- Robert Clifford - NED
- Christopher Mews - NED